CN1266161C - 单磷酸阿糖腺苷的合成工艺 - Google Patents
单磷酸阿糖腺苷的合成工艺 Download PDFInfo
- Publication number
- CN1266161C CN1266161C CN 200410015563 CN200410015563A CN1266161C CN 1266161 C CN1266161 C CN 1266161C CN 200410015563 CN200410015563 CN 200410015563 CN 200410015563 A CN200410015563 A CN 200410015563A CN 1266161 C CN1266161 C CN 1266161C
- Authority
- CN
- China
- Prior art keywords
- phosphate
- monophosphate
- vidarabine
- reaction
- vidarabine phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 10
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims description 12
- 230000008569 process Effects 0.000 title description 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 title description 2
- 229960005305 adenosine Drugs 0.000 title description 2
- 150000004712 monophosphates Chemical class 0.000 title 1
- UDMBCSSLTHHNCD-UHTZMRCNSA-N [(2r,3s,4s,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O UDMBCSSLTHHNCD-UHTZMRCNSA-N 0.000 claims abstract description 25
- 238000006243 chemical reaction Methods 0.000 claims abstract description 17
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims abstract description 9
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims abstract description 8
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000005893 bromination reaction Methods 0.000 claims abstract description 6
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 230000031709 bromination Effects 0.000 claims abstract description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims abstract description 4
- 238000004176 ammonification Methods 0.000 claims abstract description 4
- 239000003456 ion exchange resin Substances 0.000 claims abstract description 4
- 229920003303 ion-exchange polymer Polymers 0.000 claims abstract description 4
- 239000000376 reactant Substances 0.000 claims abstract description 4
- 238000006735 epoxidation reaction Methods 0.000 claims abstract description 3
- 229950006790 adenosine phosphate Drugs 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 7
- 238000005984 hydrogenation reaction Methods 0.000 claims description 6
- 229960003636 vidarabine Drugs 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- BHVOFCPOXNYVCE-UHFFFAOYSA-N 6-amino-7,9-dihydropurine-8-thione Chemical compound NC1=NC=NC2=C1NC(=S)N2 BHVOFCPOXNYVCE-UHFFFAOYSA-N 0.000 abstract 2
- 238000006640 acetylation reaction Methods 0.000 abstract 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108020005202 Viral DNA Proteins 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- -1 Hydrogen sodium oxide Chemical class 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229910001948 sodium oxide Inorganic materials 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 229940048102 triphosphoric acid Drugs 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000001246 bromo group Chemical class Br* 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- OEERIBPGRSLGEK-UHFFFAOYSA-N carbon dioxide;methanol Chemical compound OC.O=C=O OEERIBPGRSLGEK-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Landscapes
- Saccharide Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410015563 CN1266161C (zh) | 2004-03-05 | 2004-03-05 | 单磷酸阿糖腺苷的合成工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410015563 CN1266161C (zh) | 2004-03-05 | 2004-03-05 | 单磷酸阿糖腺苷的合成工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1560065A CN1560065A (zh) | 2005-01-05 |
CN1266161C true CN1266161C (zh) | 2006-07-26 |
Family
ID=34440414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410015563 Expired - Lifetime CN1266161C (zh) | 2004-03-05 | 2004-03-05 | 单磷酸阿糖腺苷的合成工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1266161C (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103204890B (zh) * | 2013-02-22 | 2016-03-09 | 广东先强药业有限公司 | 一种磷酸化法制备单磷酸阿糖腺苷的方法 |
CN103159815B (zh) * | 2013-03-22 | 2014-11-19 | 海南中化联合制药工业股份有限公司 | 单磷酸阿糖腺苷结晶化合物、药物组合物及其制备方法 |
CN107056862B (zh) * | 2017-03-24 | 2020-12-29 | 甘肃成纪生物药业有限公司 | 一种单磷酸阿糖腺苷的合成方法 |
CN107141328A (zh) * | 2017-06-14 | 2017-09-08 | 上海华理生物医药有限公司 | 一种单磷酸阿糖腺苷新晶型及其制备方法 |
CN113173957B (zh) * | 2021-04-28 | 2023-10-27 | 海南锦瑞制药有限公司 | 单磷酸阿糖腺苷的合成方法及应用 |
-
2004
- 2004-03-05 CN CN 200410015563 patent/CN1266161C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1560065A (zh) | 2005-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100564537C (zh) | 胞磷胆碱钠的制备方法 | |
CN111676259B (zh) | 一种糖核苷酸及其衍生物的制备方法 | |
CN1302004C (zh) | 一种阿糖胞苷的制备方法 | |
CN102286046B (zh) | 一种利巴韦林的制备方法 | |
CN1266161C (zh) | 单磷酸阿糖腺苷的合成工艺 | |
CN102127135B (zh) | 一种嘧啶类核苷化合物或嘌呤类核苷化合物的制备方法 | |
CN102827902B (zh) | 一种化学-生物酶法组合制备2′-脱氧尿苷的方法 | |
CN102268057B (zh) | 一种3’,5’-环腺苷单磷酸的结晶方法 | |
CN101724001A (zh) | 一类药用嘧啶衍生物的合成方法 | |
CN101333175A (zh) | 制备d-天冬酰胺及d-高丝氨酸的方法 | |
CN108409818B (zh) | 一种合成胞嘧啶核苷的方法 | |
CN116479068A (zh) | 一种利用生物酶制备n1-甲基-假尿苷单磷酸的方法 | |
CN112940058B (zh) | 一种氟标签及其制备方法、辅助的酶法合成寡糖链的方法 | |
CN101503432A (zh) | 5’-脱氧核苷单磷酸的制备方法 | |
CN105237602A (zh) | 一种2-氨基阿糖腺苷的制备方法 | |
CN102168123A (zh) | 一种制备脱氧核糖核苷三磷酸的新方法 | |
CN103242432B (zh) | 通过氢亚磷酸二酯中间体合成磷氨米酮的方法 | |
CN110846361A (zh) | 一种固定化酶法制备二磷酸尿苷葡萄糖的方法 | |
CN114057813B (zh) | 一种合成胞二磷胆碱钠的方法 | |
CN1176096C (zh) | 以肌苷(ir)为起始原料用液氨法生产腺苷(ar)的工艺 | |
WO2022227117A1 (zh) | 单磷酸阿糖腺苷的合成方法及应用 | |
CN1872868A (zh) | 一种地丹诺辛的合成方法 | |
US5968783A (en) | Process for the preparation of sugar nucleotides | |
CN116253766A (zh) | 一种环二核苷酸2’,3’-cGAMP的制备方法 | |
CN111233943A (zh) | 一种l-核酮糖的化学法生产工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGDONG JING HAO PHARMACEUTICAL TECHNOLOGY DEVE Free format text: FORMER OWNER: CHEN TIEQIAN Effective date: 20050729 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050729 Address after: 510403 Guangzhou City Airport district west of Le Jia Lu Hui Mei court room E305 Applicant after: GUANGDONG KINGHO PHARMACEUTICAL RANDD Co.,Ltd. Address before: 510250, C51, Everbright Garden, Haizhuqu District, Guangdong, Guangzhou 406, China Applicant before: Chen Tieqian |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 510000 Room 204, Yan Yuan Road, Tianhe District, Guangzhou, Guangdong, 204 Patentee after: Guangdong Beijing Hao Biological Pharmaceutical Co.,Ltd. Address before: Guangzhou Airport West District Le Jia Road Hui Mei Yuan E305 room Patentee before: GUANGDONG KINGHO PHARMACEUTICAL RANDD Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060726 |